Latest Conference Articles

June 24th 2017, 12:43am

European Hematology Association Congress

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

June 24th 2017, 12:36am

European Hematology Association Congress

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

June 23rd 2017, 11:51pm

European Hematology Association Congress

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

June 23rd 2017, 11:50pm

European Hematology Association Congress

Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.

June 23rd 2017, 11:16pm

European Hematology Association Congress

Jorge E. Cortes, MD, discusses ongoing advances with FLT3 inhibitors in acute myeloid leukemia.

June 22nd 2017, 8:37pm

European Hematology Association Congress

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia.

June 17th 2017, 11:32pm

International Conference on Malignant Lymphoma

Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.

June 17th 2017, 11:04pm

International Conference on Malignant Lymphoma

Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.

June 17th 2017, 11:01pm

International Conference on Malignant Lymphoma

Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.

June 17th 2017, 10:35pm

International Conference on Malignant Lymphoma

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

June 17th 2017, 9:18pm

International Conference on Malignant Lymphoma

Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.

June 17th 2017, 8:54pm

International Conference on Malignant Lymphoma

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

June 17th 2017, 12:45am

International Conference on Malignant Lymphoma

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

June 16th 2017, 10:39pm

International Conference on Malignant Lymphoma

BGB-3111, a highly specific BTK inhibitor, is active in patients with Waldenström macroglobulinemia, according to an interim analysis from an ongoing phase I trial.

June 16th 2017, 9:08pm

International Conference on Malignant Lymphoma

Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.

June 16th 2017, 6:29pm

International Conference on Malignant Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

June 16th 2017, 6:17pm

International Conference on Malignant Lymphoma

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

June 16th 2017, 1:06am

International Conference on Malignant Lymphoma

Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced EZH2-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.

June 15th 2017, 10:39pm

International Conference on Malignant Lymphoma

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

June 15th 2017, 7:35pm

International Conference on Malignant Lymphoma

Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.